Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases.
1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? (0:11)
2. Could you tell us a little about the RESORT study design? (1:15)
3. What were the findings of the study? (1:50)
4. Why do you think sorafenib has no effect on relapse-free survival? (3:17)
5. What will be the next steps in this clinical investigation? (4:06)
Speaker disclosures: Giuseppe Procopio serves on the advisory board for Bayer, Bristol-Myers Squibb, Ipsen, Novartis and Pfizer.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Renal Cancer
Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial
Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR […]
Lorenza Rimassa, ESMO 2019 – COSMIC-312 study in hepatocellular carcinoma
We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Questions 1. What are the limitations of current first-line treatment strategies for advanced hepatocellular carcinoma? (0:05) 2. What is the rationale for combining cabozantinib with […]
James Brugarolas, ASCO 2019 – Advances in sarcomatoid RCC
At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm. Questions 1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04) 2. What are the major treatment challenges in sarcomatoid RCC? (0:54) 3. Why is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!